微芯生物：2025年预盈5346万元左右 同比扭亏为盈

Core Viewpoint - Microchip Biotech (688321) is expected to achieve a net profit of approximately 53.46 million yuan for the fiscal year 2025, marking a turnaround from losses in the previous year [1] Financial Performance - The company anticipates a net loss of 115 million yuan attributable to shareholders for the fiscal year 2024 [1] - Sales revenue from Seglitazone increased by approximately 123% year-on-year [1] - Sales revenue from Sidaprim increased by approximately 16% year-on-year [1]